Evaluation of the transfusion safety of blood products and determination of plasma concentrations of acitretin and etretinate in patients receiving transfusions

Transfusion

Volumn 48, Issue 11, 2008, Pages 2395-2400

  Park, Hyung Doo ^b   Kim, Hye Kyung ^b   Kim, Jong Won ^b   Kim, Dae Won ^b   Lee, Joo Heung ^b   Huh, Wooseong ^b   Youn, Jai Il ^b   Kim, Hyung Gun ^b   Kim, Yoon Gyoon ^b   Kim, Myung Hwa ^b   Lee, Soo Youn ^a  

^a Samsung Medical Center   (South Korea)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BLOOD CLOTTING FACTOR; ETRETIN; ETRETINATE; IMMUNOGLOBULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SAFETY; PROTEIN BLOOD LEVEL; PSORIASIS; TERATOGENESIS;

ACITRETIN; ADOLESCENT; ADULT; AGED; BIOLOGICAL PRODUCTS; BLOOD DONORS; BLOOD TRANSFUSION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CONTAMINATION; ETRETINATE; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; TERATOGENS;

EID: 55349095449     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.01850.x     Document Type: Article

References (25)

1. van de Kerkhof PC, Vissers WH. Established treatments of psoriasis. Curr Drug Targets Inflamm Allergy 2004 3 : 145 56.
2. van de Kerkhof PC. The management of psoriasis. Neth J Med 1998 52 : 40 5.
3. Halioua B, Saurat JH. Risk : benefit ratio in the treatment of psoriasis with systemic retinoids. Br J Dermatol 1990 122 Suppl 36 : 135 50.
4. Geiger JM, Baudin M, Saurat JH. Teratogenic risk with etretinate and acitretin treatment. Dermatology 1994 189 : 109 16.
5. Soriatane (acitretin) capsules complete product information. Nutley (NJ): Roche Pharmaceuticals 2003.
6. Blood management law. The republic of Korea : Ministry of Health and Welfare 2005.
7. Standards for blood banks and transfusion services. 23rd ed. Bethesda (MD) : American Association of Blood Banks 2005.
8. United Kingdom Blood Transfusion Services and National Institute for Biological Standards and Control. Whole blood and apheresis donor selection guidelines. 201st ed. Southampton : UK Blood Transfusion Services and National Institute 2004.
9. Surber C, Laugier JP, Geiger JM, Bun H, Durand A, Maibach HI. High-performance liquid chromatography determination of acitretin in plasma and its application to a pharmacokinetic study in human subjects. Pharm Res 1992 9 : 1365 9.
10. Berne B, Rollman O, Vahlquist A. UV-induced isomerization of oral retinoids in vitro and in vivo in hairless mice. Photodermatol Photoimmunol Photomed 1990 7 : 146 52.
11. Massarella J, Vane F, Bugge C, Rodriguez L, Cunningham WJ, Franz T, Colburn W. Etretinate kinetics during chronic dosing in severe psoriasis. Clin Pharmacol Ther 1985 37 : 439 46.
12. De Leenheer AP, Lambert WE, De Bersaques JP, Kint AH. High-performance liquid chromatographic determination of etretinate and all-trans- and 13-cis-acitretin in human plasma. J Chromatogr 1990 500 : 637 42.
13. Disdier B, Bun H, Catalin J, Durand A. Simultaneous determination of all-trans-, 13-cis-, 9-cis-retinoic acid and their 4-oxo-metabolites in plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1996 683 : 143 54.
14. Jakobsen P, Larsen FG, Larsen CG. Simultaneous determination of the aromatic retinoids etretin and etretinate and their main metabolites by reversed-phase liquid chromatography. J Chromatogr 1987 415 : 413 8.
15. Stichtenoth DO, Deicher HR, Frolich JC. Blood donors on medication. Are deferral periods necessary? Eur J Clin Pharmacol 2001 57 : 433 40.
16. Grønhøj Larsen F, Steinkjer B, Jakobsen P, Hjorter A, Brockhoff PB, Nielsen-Kudsk F. Acitretin is converted to etretinate only during concomitant alcohol intake. Br J Dermatol 2000 143 : 1164 9.
17. Grønhøj Larsen F, Jakobsen P, Knudsen J, Weismann K, Kragballe K, Nielsen-Kudsk F. Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol 1993 100 : 623 7.
18. Maier H, Hönigsmann H. Assessment of acitretin-treated female patients of childbearing age and subsequent risk of teratogenicity. Br J Dermatol 2001 145 : 1028 9.
19. Maier H, Hönigsmann H. Concentration of etretinate in plasma and subcutaneous fat after long-term acitretin. Lancet 1996 348 : 1107.
20. Sturkenboom MC, Berg LT, van Voorst-Vader PC, Cornel MC, Stricker BH, Wesseling H. Inability to detect plasma etretinate and acitretin is a poor predictor of the absence of these teratogens in tissue after stopping acitretin treatment. Br J Clin Pharmacol 1994 38 : 229 35.
21. Löfberg B, Reiners J, Spielmann H, Nau H. Teratogenicity of steady-state concentrations of etretinate and metabolite acitretin maintained in maternal plasma and embryo by intragastric infusion during organogenesis in the mouse: a possible model for the extended elimination phase in human therapy. Pharmacol Ther 1990 15 : 45 51.
22. Berbis P, Bun H, Geiger JM, Rognin C, Durand A, Serradimigni A, Hartmann D, Privat Y. Acitretin (RO10-1670) and oral contraceptives: interaction study. Arch Dermatol Res 1988 280 : 388 9.
23. Geiger JM, Baudin M, Saurat JH. Teratogenic risk with etretinate and acitretin treatment. Dermatology 1994 189 : 109 16.
24. de Die-Smulders CE, Sturkenboom MC, Veraart J, van Katwijk C, Sastrowijoto P, van der Linden E. Severe limb defects and craniofacial abnormalities in a fetus conceived during acitretin therapy. Teratology 1995 52 : 215 9.
25. Barbero P, Lotersztein V, Bronberg R, Perez M, Alba L. Acitretin embryopathy: a case report. Birth Defects Res Part A Clin Mol Teratol 2004 70 : 831 3.